Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ: VKTX )

30.48 +0.98 (+3.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
21 22 Next >
MSTR Stock Alert: MicroStrategy Releases New AI Bot
MicroStrategy stock is up on Tuesday as investors in MSTR shares react to news of a new AI bot released by the data analytics company. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Is Viking Therapeutics (VKTX) Stock Up 24% Today?
Viking Therapeutics stock is rising higher on Tuesday as investors in VNKTX shares react to positive Phase 1 clinical trial results. 
Via InvestorPlace
Viking Therapeutics' Investigational Oral Obesity Drug Shows Reduced Weight In Small Study
Explore Viking Therapeutics' Phase 1 MAD trial results for oral VK2735, a promising treatment for metabolic disorders like obesity. Dose-dependent reductions in body weight, encouraging... 
Via Benzinga
Viking Therapeutics: Buy, Sell, or Hold?
It has a promising candidate and plenty of cash in hand. 
Via The Motley Fool
Viking Surges After Weight-Loss Pill Tops Expectations In Just 28 Days
People lost more weight than the company expected over a 28-day study. 
Via Investor's Business Daily
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
All three of these high-flying stocks could have more room to run. 
Via The Motley Fool
2 Incredible Growth Stocks to Buy Right Now
These two biotech stocks could be big winners in the years ahead. 
Via The Motley Fool
Viking Therapeutics Unusual Options Activity For March 19
Via Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
Don't bet on this pitfall happening, but know that it's a possibility. 
Via The Motley Fool
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
Find out why investment banks up and down Wall Street have big expectations for these stocks. 
Via The Motley Fool
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants. 
Via The Motley Fool
Is Viking Therapeutics Stock a Millionaire Maker?
Viking Therapeutics has become one of the hottest healthcare stocks of 2024. 
Via The Motley Fool
Where Will Viking Therapeutics Stock Be in 10 Years?
Viking's future appears to be very promising, but market dynamics can change. 
Via The Motley Fool
Where Will Viking Therapeutics Be in 5 Years?
Expectations for the stock are high, and it could well deliver. 
Via The Motley Fool
Will Viking Therapeutics Get Acquired?
Would an acquisition be good news for Viking Therapeutics investors? 
Via The Motley Fool
Check Out What Whales Are Doing With VKTX
Via Benzinga
Peering Into Viking Therapeutics's Recent Short Interest
Via Benzinga
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs. 
Via The Motley Fool
Could Viking Therapeutics Become the Next Eli Lilly?
Viking shares have skyrocketed on its recent good news. 
Via The Motley Fool
Viking Therapeutics Stock Has 55% Upside, According to 1 Wall Street Analyst
The company might enter the hottest segment in the pharmaceutical sphere before long. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Don't jump on the bandwaggon too quickly. 
Via The Motley Fool
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer. 
Via The Motley Fool
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
Unleashing the Bulls: 3 Top Stocks to Charge Ahead in March
This environment presents a compelling opportunity for investors seeking growth. Discover 3 top stocks primed for long-term growth in 2024. 
Via InvestorPlace
Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?
Viking aims to enter a market that may be worth $100 billion in a few years. 
Via The Motley Fool
1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
The pharma giant could have yet another knockout obesity drug on the way. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.